Skip to main content
OpenTrials
Completed

NCT Number: NCT00204061

Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis

The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year–36 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Psychiatry and Psycotherapy University of Cologne

Cologne, North Rhine-Westphalia, 50924, Germany

About this study

The first diagnosis of schizophrenia is preceded by a long lasting period comprising an untreated psychotic and a prodromal state. The duration of untreated psychosis correlates with a significant worsening of several outcome variables and persons fulfilling criteria of a prodromal state are already suffering from prodromal symptoms and from a significant deterioration of social and vocational functioning. However, a sufficient strategy for early intervention is still lacking. The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. For analysis 130 patients will be recruited within three years, the treatment period is two years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General criteria
  • Age between 14 and 36 years
  • male or female, in- or outpatients
  • written informed consent, for patients below 18 years also signed by parents
  • Special criteria (present within the last three months prior to the study)
  • Attenuated Positive Symptoms (APS)
  • Presence of at least one of the following symptoms: ideas of reference, odd beliefs or magical thinking, unusual perceptual experiences, odd thinking and speech, suspiciousness or paranoid ideation
  • Symptoms have to appear several times per week for a period of at least one week

AND / OR

  • Brief Limited Intermittent Psychotic Symptoms (BLIPS)
  • Duration of episode less than one week, interval between episodes at least one week
  • Symptoms resolve spontaneously
  • Presence of at least one of the following symptoms: Hallucinations, Delusions, Formal thought disorder, Gross disorganized or catatonic behavior

Exclusion criteria

  • Diagnostic and Statistical Manual of Mental Disorders (DSM) IV diagnosis of schizophrenia, schizophreniform,schizoaffective, delusional or bipolar disorder, at any time of life.
  • DSM-IV diagnosis of brief psychotic episode with a duration of more than one week, at any time time of life, or BLIPS within one week before inclusion.
  • DSM-IV diagnosis of delirium, dementia, amnestic and other cognitive disorders, mental retardation, mental disorders due to a general medical condition or mental disturbances due to psychotropic substances.
  • Abuse of alcohol or drugs within the last three months prior to the study; exception: cannabis user have to be drug-free during four weeks prior to the study. In case of drug abuse, it has to be determined, whether present prodromal symptoms appeared before any drug abuse; If not, symptoms have to be still present after a drug-free period of 3 months (hallucinogens, amphetamines), or four weeks (cannabis).

Treatment and study plan

Supportive management

Behavioral

The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.

Other names: Clinical Management

Amisulpride

Drug

Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.

Other names: Solian

Primary outcomes

  1. improvement of risk related symptoms

    Time frame: 3, 6, 12, 24 months

    Decrease of symptom scores; complete remission of risk related symptoms

Secondary outcomes

  1. Global functioning

    Time frame: 3, 6, 12, 24 months

    Increase of Global Assessment of Functioning (GAF) scores

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Collaborators

  • Department of Psychiatry University of Bonn
  • German Federal Ministry of Education and Research
  • German Research Network On Schizophrenia
  • Heinrich-Heine University, Duesseldorf
  • Ludwig-Maximilians - University of Munich
  • Sanofi-Synthelabo

Registry information

Important dates

Study start
2001
Primary completion
2005
Study completion
2005
First posted
Sep 20, 2005
Registry last updated
Dec 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.